Otsuka Pharmaceutical Companies (U.S.)’s Post

Did you miss Avance Clinical's live Psychedelics In Focus webinar on Monday? The webinar featured a fascinating conversation between Senior Director of Scientific and Regulatory Services, Jorgen Mould and Senior Vice President Scientific and Regulatory Affairs Kevin Leach, Ph.D, DABT. Delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. Simply register via the Xtalks website 👇 https://lnkd.in/eywUiP3i #AvanceClinical #CRO #psychedelicscience #psychedelicresearch #clinicalresearch #newmedicines #depression #anxiety #webinar

🚨 BREAKING NEWS 🚨 Multidisciplinary Association for Psychedelic Studies (MAPS) has finally published their much-anticipated MAPP2 Phase 3 MDMA trial results, and the news is next level. The MAPP2 study evaluated the efficacy and safety of MDMA-assistant therapy for PTSD, and successfully showed that participants in the study experienced a clinically meaningful improvement, with many participants even no longer meeting the diagnostic requirements for PTSD, and over 80% experiencing a more than 10 point severity score reduction in total severity score. There were no serious safety incidents reported, nor any issues with abuse or dependency. This is major news for the psych world, and this publication of such positive Phase 3 results is a significant step forward towards submitting a new drug application to the FDA in 2023. We’ll be going live on YouTube around 4 p.m. EST to discuss this huge development. Be sure to tune in 👀 https://lnkd.in/g93pFFaC #ptsd #psychedelics #psychedelictherapy #psychedelicresearch #mdma

LIVE WEBINAR 💻 💊 Monday November 27 10am PST / 12pm CST / 1pm EST (US TIME) Please join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. Our expert panellists Jorgen Mould and Kevin Leach, Ph.D, DABT will provide invaluable insights into ongoing trials, innovations in psychedelic therapies, and the regulatory pathways shaping the future of mental health treatment. Don’t miss this opportunity to stay informed about the latest developments in psychedelic research and regulatory advancements. Secure your spot now for this enlightening webinar with Avance Clinical. Register now! 👇 https://lnkd.in/gpKgjCYM #AvanceClinical #CRO #clinicaltrials #drugdevelopment #psychedelics #psilocybin #depression #anxiety #PTSD #addiction #webinar #biotech

What is TMS used for? 🔎 In Australia, TMS is currently TGA-approved for the treatment of depression, with Medicare rebates now available for eligible* adult patients that have tried two or more antidepressant medications without any significant benefits to their symptoms. It is generally used for those patients who do not see improvements from other treatments. TMS may also help patients with other conditions, such as OCD, PTSD, pain management and tinnitus, with evidence continuing to emerge for a range of psychiatric and neurological conditions. 👉 For more information on TMS and how it works, visit our website at www.modalis.com.au or email our friendly team at tms@modalis.com.au. #tms #tmstherapy #tmsaustralia #rtms #transcranialmagneticstimulation #repetitivetranscranialmagneticstimulation #brainstimulation #neuroscienceaustralia #perthclinic #perth

My dad was a veteran and police officer who died by suicide due to chronic pain. Veterans, police, and those struggling with pain may not have considered psychotherapy to manage their pain. A new study (June 13, JAMA Network Open, "A New Psychotherapeutic 'Gold Standard' for Chronic Pain?") found that a single course of treatment with emotional awareness and expression therapy (EAET) was associated with a significantly greater reduction in chronic pain severity than cognitive-behavioral therapy (CBT). The study compared EAET with CBT. Two-thirds of patients who received EAET reported a 30% reduction in pain, compared with 17% of those who received CBT. Those with depression and anxiety responded more favorably to EAET. In EAET, they were asked to recall a difficult or traumatic memory, engage in experiencing how emotions feel in the body, express feelings, and let them go. This contrasts with CBT, the current gold standard for chronic pain. CBT focuses on tolerating pain through guided imagery, muscle relaxation, and exercises, and adapting thinking to change thinking about pain. The trial enrolled 126 veterans (92% men; 55% black or African American) aged 60–95 years with at least 3 months of musculoskeletal pain. More than two-thirds of individuals had a psychiatric diagnosis; one-third had PTSD. Almost all had back pain, and many had pain in multiple locations. The study demonstrated that expressing emotions is superior to the cognitive discussion of these emotions in the therapy of patients with chronic pain. #Compassionfatigue #vicarioustrauma #suicideprevention #veterans #mentalhealth #painmanagement

Tell your friends. Let’s change the narrative around mental health, one float at a time. #REST #floatlife #float #floattherapy #floating #selfcare #wellness #spalifestyle #spa #Tucson #BearDown #uofa #isolation #metime #emotionalwellness #mentalhealth #recovery #epsom #healthandwellness #mensmentalhealth #endthestigma #interoception

When I published my first float study back in 2018 (https://lnkd.in/gFT2RkQQ), it was the first time that anyone had systematically examined the safety and efficacy of floating in a sample with rather severe anxiety and depression, including patients with PTSD. In my mind, one of the most surprising findings from that initial float study was the overall lack of any negative side effects. Going into the study, I was worried about all sorts of adverse effects; everything from panic attacks, to flashbacks, to hallucinations had crossed my mind as possibilities. I waited patiently for the first patient to scream out loud through the intercom system, but it never happened. I thought for sure that most patients would only be able to tolerate 20-30 minutes alone by themselves in the float environment, but they ended up floating for the entire hour, and afterwards said they wanted to float longer. Their float experience was remarkably positive, so much so that we went out of our way to transcribe each patient's post-float debriefing interview that we ended up publishing in the supplement (https://lnkd.in/gdkytK84). As excited as I was by these initial findings, I had to temper my excitement because this was only a single float session, and we had no idea if it could be replicated across multiple float sessions. In order to find out, I applied for an NIH grant that was funded by the National Center for Complementary and Integrative Health. Just getting the grant was a major win, as the NIH had never funded a float study before (which is quite perplexing given that the first iteration of the float tank was built at the National Institute of Mental Health back in the 1950's!) Running clinical trials with multiple sessions is quite difficult and costly in its own right. Now try doing it during a global pandemic in a sample of chronically anxious patients who's number one response to adversity in life is avoidance! This was quite a feat, and it would have never been possible without the herculean efforts of my close friend and colleague Dr. Sahib Khalsa and the amazing staff at the Laureate Institute for Brain Research. In particular, I want to acknowledge Raminta Wilson, who was able to successfully navigate this study through the pandemic, and Dr. McKenna Garland, who completed this study as part of her dissertation and did an absolutely incredible job of writing up the results! I'm very excited to finally see these results published and even more excited to see that the notable lack of side effects found in my original 2018 study has now been replicated across multiple float sessions. More research is always necessary, but these findings provide the Float Research Collective with an important and necessary foundation to build on. The study, along with a repository of all the other peer-reviewed clinical float research can be found at https://lnkd.in/gHYJKvn4

FIRST NIH-FUNDED FLOAT STUDY JUST RELEASED! LINK BELOW ⬇ Please share with the world!! Black box warnings are everywhere these days. It shows how common major safety concerns have become, especially for medications targeting depression and anxiety. Most antidepressant medications like SSRIs now contain a suicide warning, and anti-anxiety medications using benzodiazepines have an addiction warning. Adverse events can also occur with psychedelics, and just this week, an FDA advisory committee rejected MDMA for the treatment of PTSD, with many reviewers commenting on the lack of safety data. Indeed safety issues and side effects can be found with behavioral interventions too, like psychotherapy and even meditation. Given this context, it is no wonder that the 1st float study funded by the NIH is focused on safety. The results were published today and make a compelling argument for the safety of floatation therapy in individuals with clinical depression and anxiety, including PTSD. There were no serious adverse events, minimal negative side effects, and numerous positive side effects. If floating were a pill, everyone would take it! The study is open access and freely available to read and share online at: https://lnkd.in/gN8nPrc7 #PTSDAwarenessMonth

💪 If we can, we must, and we should.......we need to improve treatments for depression and related mental health conditions urgently! 🔥 That's exactly what we've set out to do in this important work and the data is starting to look overwhelmingly compelling that we have a scalable treatment solution in microdosing MB22001 to treat depression. Of course, more evidence and work is required so MindBio is progressing to late stage clinical trials. 😀 MindBio's Phase 2B take-home microdosing MB22001 trial in patients with Major Depressive Disorder has been given the final regulatory go ahead and will start dosing first patients on 11 March 2024.

June is #PTSDAwarenessMonth and it's crucial to spread the word that treatments can significantly improve quality of life. Our expertise and innovative technology help study teams recognize, diagnose, and assess changes in PTSD patients. Learn more: https://hubs.li/Q02CP7_w0